πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

287 results for β€œOno” Clear

  1. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  2. 90 grams of Crystalline Lactulose

    CUMBERLAND PHARMACEUTICALS INC

    Colonoscopy Preparation

    phase 2 small molecule completed

    1 trial

  3. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Hemostasis

    phase 2 small molecule completed

    1 trial

  4. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Bone Mineral Density

    phase 2 small molecule completed

    1 trial

  5. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Migraine

    phase 2 small molecule completed

    1 trial

  6. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extensionβ€”assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic Ξ²-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  7. A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 other active

    1 trial

  8. A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

    Incyte

    Anaemia associated with myelofibrosis

    phase 2 other active

    1 trial

  9. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

    Shionogi B.V.

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial

  10. A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic Uveal MElanoma patients

    The George Institute

    Metastatic uveal melanoma

    phase 2 other active

    1 trial

  11. ASTX727

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial

  12. AZD2962, AZD2962

    AstraZeneca AB

    Myelodysplastic syndromes, Dysplastic chronic myelomonocytic leukaemia

    phase 2 small molecule active

    1 trial

  13. Anti-CD40 Agonist Monoclonal Antibody CDX-1140

    United Therapeutics Europe Ltd

    Ovarian Clear Cell Adenocarcinoma

    phase 2 mab active

    1 trial

  14. Anti-human CCL24 monoclonal antibody (CM-101)

    Chemomab Therapeutics

    Primary Sclerosing Cholangitis

    phase 2 mab active

    1 trial

  15. Arm 1： Standard Synchronous Group

    The First People's Hospital of Lianyungang

    Advanced Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  16. Atacicept 75 mg

    Serono Europe Limited

    Lupus Erythematosus, Systemic

    phase 2 small molecule terminated

    1 trial

  17. Autologous (self) mononuclear cells derived from umbilical cord blood

    Regeneron Ireland Designated Activity Company (DAC)

    Hypoplastic Left Heart Syndrome

    phase 2 mab active

    1 trial

  18. Autologous Bone Marrow Mononuclear Cells

    Lxo Ireland Designated Activity Company

    Peripheral Vascular Diseases

    phase 2 other completed

    1 trial

  19. Autologous bone marrow mononuclear cell transplantation

    EuroGen Pharmaceuticals Ltd

    Spinal Cord Injury

    phase 2 mab terminated

    1 trial

  20. Bexmarilimab

    Lacuna Pharma Pty Ltd

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  21. Bone marrow mononuclear cells

    Lxo Ireland Designated Activity Company

    Chronic Myocardial Ischemia

    phase 2 other completed

    1 trial

  22. Busulfan

    Children's Hospital of Fudan University

    Juvenile Myelomonocytic Leukemia

    phase 2 small molecule completed

    1 trial

  23. CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

    BEONE MEDICINES AUS PTY LTD

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  24. CRB-601 monoclonal antibody

    Corbus Pharmaceuticals Holdings

    Solid Tumor

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources